drugset / Trial / NCT02721875
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome (MDS) after hypomethylating agents (HMA) treatment failure.
Timeline
- Start
- 2016-04-28
- Primary completion
- 2016-06-29
- Completion
- 2016-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volasertib | Small molecule | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | — |